Related Experiment Video
Updated: Apr 22, 2026
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic
John F Castro-Alvarez1, S Alejandro Uribe-Arias1, Kenneth S Kosik2
1Cellular and Molecular Neurobiology Area, Neuroscience Group of Antioquia, Faculty of Medicine, University Research Headquarters, University of Antioquia Medellín Colombia.
Abstract:
CDK5 is a member of the cyclin-dependent kinase family with diverse functions in both the developing and mature nervous system. The inappropriate activation of CDK5 due to the proteolytic release of the activator fragment p25 from the membrane contributes to the formation of neurofibrillary tangles and chronic neurodegeneration. At 18 months of age 3xTg-AD mice were sacrificed after 1 year (long term) or 3 weeks (short term) of CDK5 knockdown. In long-term animals CDK5 knockdown prevented insoluble Tau formation in the hippocampi and prevented spatial memory impairment. In short-term animals, CDK5 knockdown showed reduction of CDK5, reversed Tau aggregation, and improved spatial memory compared to scrambled treated old 3xTg-AD mice. Neither long-term nor short-term CDK5 knock-down had an effect on old littermates. These findings further validate CDK5 as a target for Alzheimer's disease both as a preventive measure and after the onset of symptoms.
Insights
Targeting cyclin-dependent kinase 5 (CDK5) in Alzheimer
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Cyclin-dependent kinase 5 (CDK5) plays critical roles in the nervous system.
- Inappropriate CDK5 activation, via p25 fragment release, is linked to neurofibrillary tangles and neurodegeneration.
- Alzheimer's disease (AD) pathology involves tau aggregation and cognitive decline.
Purpose of the Study:
- To investigate the therapeutic potential of CDK5 knockdown in a mouse model of Alzheimer's disease.
- To assess the effects of short-term and long-term CDK5 inhibition on AD pathology and spatial memory.
Main Methods:
- Utilized 3xTg-AD mice, an established model for Alzheimer's disease.
- Administered CDK5 knockdown for short-term (3 weeks) and long-term (1 year) durations in aged mice.
- Evaluated insoluble Tau formation, CDK5 levels, and spatial memory performance.
Main Results:
- Long-term CDK5 knockdown prevented insoluble Tau formation and spatial memory deficits in 3xTg-AD mice.
- Short-term CDK5 knockdown reduced CDK5, reversed Tau aggregation, and improved spatial memory.
- CDK5 knockdown did not affect age-matched wild-type littermates.
Conclusions:
- CDK5 is a validated therapeutic target for Alzheimer's disease.
- CDK5 inhibition shows promise for both preventing and treating established AD symptoms.
- Targeting CDK5 offers a potential strategy for managing tauopathy and cognitive impairment in AD.
More Related Videos
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
17:45T-maze Forced Alternation and Left-right Discrimination Tasks for Assessing Working and Reference Memory in Mice
Published on: February 26, 2012